Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

Mar 12, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has partnered with Bristol-Myers Squibb to develop a companion diagnostic for a number of cancer immunotherapies, with an initial focus on colorectal cancer (CRC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

What's Popular?

In Molecular Diagnostics

  1. Abbott Q3 Diagnostics Revenues Increase 38 Percent

  2. Danaher Q3 Revenues Up 35 Percent

  3. Thermo Fisher Scientific Q3 Revenues Soar 36 Percent

  4. COVID-19 Testing Plays Into Abbott's Long-Term Diagnostic Strategy

    Premium

  5. BD, CerTest Biotec Get CE-IVD Mark for Combination COVID-19, Influenza, RSV Test on BD Max

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.